Avadel Pharmaceuticals plc
| NASDAQ: AVDL | Healthcare / Drug Manufacturers / Ireland |
| 8.78 | 0 | 0.00 | Vol 161.31K | 1Y Perf -8.63% |
| Apr 9th, 2021 16:00 DELAYED |
| BID | 8.51 | ASK | 9.13 | ||
| Open | 8.79 | Previous Close | 8.78 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 18.13 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 106.49 | Finscreener Ranking | ★★★★★ 60.29 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★+ 60.54 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★★+ 67.03 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 513.32M | Earnings Rating | Strong Sell | |
| Price Range Ratio 52W % | 45.61 | Earnings Date | 10th May 2021 |
Today's Price Range 8.648.85 | 52W Range 4.8313.49 | 5 Year PE Ratio Range -7.6017.60 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -2.98% | ||
| 1 Month | -4.57% | ||
| 3 Months | 28.36% | ||
| 6 Months | 56.23% | ||
| 1 Year | -8.63% | ||
| 3 Years | 12.85% | ||
| 5 Years | -25.91% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -47.95 | |||
ROE last 12 Months | 10.77 | |||
ROA (5Y Avg) | -9.14 | |||
ROA last 12 Months | 2.95 | |||
ROC (5Y Avg) | -10.21 | |||
ROC last 12 Months | 12.55 | |||
Return on invested Capital Q | -2.91 | |||
Return on invested Capital Y | 8.51 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.30 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 180.80 | ||||
| 3.26 | ||||
| 52.43 | ||||
| 16.60 | ||||
| -45.20 | ||||
| -0.89 | ||||
| 3.63 | ||||
| 2.78 | ||||
| 438.24M | ||||
| Forward PE | -36.20 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 17.20 | ||||
| 17.40 | ||||
| 0.44 | ||||
| 0.80 | ||||
| 0.60 | ||||
| Leverage Ratio | 1.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 74.30 | ||||
| 35.40 | ||||
| 43.00 | ||||
| -38.60 | ||||
| 91.09 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 10.09M | ||||
| 0.17 | ||||
| -33.41 | ||||
| -13.06 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.28 | -0.24 | 14.29 |
| Q03 2020 | -0.26 | -0.20 | 23.08 |
| Q02 2020 | -0.18 | -0.16 | 11.11 |
| Q01 2020 | -0.27 | -0.02 | 92.59 |
| Q04 2019 | -0.25 | -0.07 | 72.00 |
| Q03 2019 | - | -0.24 | - |
| Q02 2019 | - | -0.23 | - |
| Q01 2019 | - | -0.35 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.32 | -28.00 | Negative |
| 6/2021 QR | -0.33 | -43.48 | Negative |
| 12/2021 FY | -1.33 | -0.76 | Negative |
| 12/2022 FY | -0.25 | 7.41 | Positive |
| Next Report Date | 10th May 2021 |
| Estimated EPS Next Report | -0.32 |
| Estimates Count | 7 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 161.31K |
| Shares Outstanding | 58.47M |
| Trades Count | 1.16K |
| Dollar Volume | 4.97M |
| Avg. Volume | 502.38K |
| Avg. Weekly Volume | 161.10K |
| Avg. Monthly Volume | 280.95K |
| Avg. Quarterly Volume | 515.59K |
Avadel Pharmaceuticals plc (NASDAQ: AVDL) stock closed at 8.78 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 161.43K shares and market capitalization of 513.32M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 50 people. Avadel Pharmaceuticals plc CEO is Gregory J. Divis.
The one-year performance of Avadel Pharmaceuticals plc stock is -8.63%, while year-to-date (YTD) performance is 31.44%. AVDL stock has a five-year performance of -25.91%. Its 52-week range is between 4.83 and 13.49, which gives AVDL stock a 52-week price range ratio of 45.61%
Avadel Pharmaceuticals plc currently has a PE ratio of 180.80, a price-to-book (PB) ratio of 3.26, a price-to-sale (PS) ratio of 52.43, a price to cashflow ratio of 16.60, a PEG ratio of 2.32, a ROA of 2.95%, a ROC of 12.55% and a ROE of 10.77%. The company’s profit margin is 91.09%, its EBITDA margin is 43.00%, and its revenue ttm is $10.09 Million , which makes it $0.17 revenue per share.
Of the last four earnings reports from Avadel Pharmaceuticals plc, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.32 for the next earnings report. Avadel Pharmaceuticals plc’s next earnings report date is 10th May 2021.
The consensus rating of Wall Street analysts for Avadel Pharmaceuticals plc is Strong Buy (1), with a target price of $18.13, which is +106.49% compared to the current price. The earnings rating for Avadel Pharmaceuticals plc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Avadel Pharmaceuticals plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Avadel Pharmaceuticals plc has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.48, ATR14 : 0.60, CCI20 : -77.02, Chaikin Money Flow : 0.01, MACD : 0.00, Money Flow Index : 36.73, ROC : -8.55, RSI : 49.55, STOCH (14,3) : 45.91, STOCH RSI : 0.83, UO : 54.29, Williams %R : -54.09), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Avadel Pharmaceuticals plc in the last 12-months were:
Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.
CEO: Gregory J. Divis
Telephone: +353 14851200
Address: 10 Earlsfort Terrace, Dublin D02 T380, , IE
Number of employees: 50
